vs
KALTURA INC（KLTR）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
KALTURA INC的季度营收约是REGENXBIO Inc.的1.5倍（$45.5M vs $30.3M），KALTURA INC净利率更高（-1.3% vs -221.3%，领先220.1%），REGENXBIO Inc.同比增速更快（43.0% vs -0.1%），KALTURA INC自由现金流更多（$3.5M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 0.8%）
Kaltura Inc是2006年成立、总部位于纽约的软件企业，业务覆盖多个核心领域：网络研讨会与虚拟活动、企业视频内容管理、在线视频平台、教育科技以及云电视软件，可提供视频门户、学习管理系统与内容管理系统扩展插件、虚拟活动与网络研讨会平台、电视流媒体应用等多款产品。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
KLTR vs RGNX — 直观对比
营收规模更大
KLTR
是对方的1.5倍
$30.3M
营收增速更快
RGNX
高出43.2%
-0.1%
净利率更高
KLTR
高出220.1%
-221.3%
自由现金流更多
KLTR
多$56.3M
$-52.8M
两年增速更快
RGNX
近两年复合增速
0.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $45.5M | $30.3M |
| 净利润 | $-575.0K | $-67.1M |
| 毛利率 | 72.4% | — |
| 营业利润率 | 1.9% | -190.0% |
| 净利率 | -1.3% | -221.3% |
| 营收同比 | -0.1% | 43.0% |
| 净利润同比 | 91.3% | -31.2% |
| 每股收益（稀释后） | — | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KLTRRGNX
| Q4 25 | $45.5M | $30.3M | ||
| Q3 25 | $43.9M | $29.7M | ||
| Q2 25 | $44.5M | $21.4M | ||
| Q1 25 | $47.0M | $89.0M | ||
| Q4 24 | $45.6M | $21.2M | ||
| Q3 24 | $44.3M | $24.2M | ||
| Q2 24 | $44.0M | $22.3M | ||
| Q1 24 | $44.8M | $15.6M |
净利润KLTRRGNX
| Q4 25 | $-575.0K | $-67.1M | ||
| Q3 25 | $-2.6M | $-61.9M | ||
| Q2 25 | $-7.8M | $-70.9M | ||
| Q1 25 | $-1.1M | $6.1M | ||
| Q4 24 | $-6.6M | $-51.2M | ||
| Q3 24 | $-3.6M | $-59.6M | ||
| Q2 24 | $-10.0M | $-53.0M | ||
| Q1 24 | $-11.1M | $-63.3M |
毛利率KLTRRGNX
| Q4 25 | 72.4% | — | ||
| Q3 25 | 70.0% | — | ||
| Q2 25 | 70.2% | — | ||
| Q1 25 | 69.7% | — | ||
| Q4 24 | 70.8% | 70.2% | ||
| Q3 24 | 66.7% | 48.8% | ||
| Q2 24 | 65.1% | 52.5% | ||
| Q1 24 | 63.9% | 72.6% |
营业利润率KLTRRGNX
| Q4 25 | 1.9% | -190.0% | ||
| Q3 25 | -3.4% | -176.3% | ||
| Q2 25 | -6.2% | -296.3% | ||
| Q1 25 | -3.4% | 13.6% | ||
| Q4 24 | -8.3% | -242.1% | ||
| Q3 24 | -10.1% | -256.6% | ||
| Q2 24 | -19.4% | -251.3% | ||
| Q1 24 | -16.3% | -408.8% |
净利率KLTRRGNX
| Q4 25 | -1.3% | -221.3% | ||
| Q3 25 | -6.0% | -208.3% | ||
| Q2 25 | -17.4% | -331.8% | ||
| Q1 25 | -2.4% | 6.8% | ||
| Q4 24 | -14.5% | -241.3% | ||
| Q3 24 | -8.1% | -246.3% | ||
| Q2 24 | -22.7% | -237.7% | ||
| Q1 24 | -24.8% | -405.4% |
每股收益（稀释后）KLTRRGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | $0.02 | $-1.20 | ||
| Q2 25 | $-0.05 | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | $0.02 | $-1.17 | ||
| Q2 24 | $-0.07 | $-1.05 | ||
| Q1 24 | — | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $51.9M | $230.1M |
| 总债务越低越好 | $29.3M | — |
| 股东权益账面价值 | $6.3M | $102.7M |
| 总资产 | $164.7M | $453.0M |
| 负债/权益比越低杠杆越低 | 4.63× | — |
8季度趋势，按日历期对齐
现金及短期投资KLTRRGNX
| Q4 25 | $51.9M | $230.1M | ||
| Q3 25 | $72.2M | $274.2M | ||
| Q2 25 | $71.2M | $323.3M | ||
| Q1 25 | $62.9M | $267.9M | ||
| Q4 24 | $81.3M | $234.7M | ||
| Q3 24 | $77.7M | $255.5M | ||
| Q2 24 | $68.3M | $290.4M | ||
| Q1 24 | $68.9M | $338.7M |
总债务KLTRRGNX
| Q4 25 | $29.3M | — | ||
| Q3 25 | $30.6M | — | ||
| Q2 25 | $31.3M | — | ||
| Q1 25 | $31.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $33.3M | — | ||
| Q2 24 | $33.7M | — | ||
| Q1 24 | $34.1M | — |
股东权益KLTRRGNX
| Q4 25 | $6.3M | $102.7M | ||
| Q3 25 | $17.7M | $161.5M | ||
| Q2 25 | $17.0M | $213.7M | ||
| Q1 25 | $22.7M | $274.2M | ||
| Q4 24 | $24.4M | $259.7M | ||
| Q3 24 | $24.1M | $301.4M | ||
| Q2 24 | $23.5M | $348.3M | ||
| Q1 24 | $25.1M | $390.7M |
总资产KLTRRGNX
| Q4 25 | $164.7M | $453.0M | ||
| Q3 25 | $172.6M | $525.2M | ||
| Q2 25 | $169.4M | $581.0M | ||
| Q1 25 | $172.8M | $490.9M | ||
| Q4 24 | $181.3M | $466.0M | ||
| Q3 24 | $178.6M | $519.1M | ||
| Q2 24 | $171.3M | $569.4M | ||
| Q1 24 | $173.1M | $629.2M |
负债/权益比KLTRRGNX
| Q4 25 | 4.63× | — | ||
| Q3 25 | 1.73× | — | ||
| Q2 25 | 1.85× | — | ||
| Q1 25 | 1.41× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.38× | — | ||
| Q2 24 | 1.43× | — | ||
| Q1 24 | 1.36× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.6M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $3.5M | $-52.8M |
| 自由现金流率自由现金流/营收 | 7.7% | -174.0% |
| 资本支出强度资本支出/营收 | 0.3% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $13.9M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流KLTRRGNX
| Q4 25 | $3.6M | $-52.3M | ||
| Q3 25 | $9.3M | $-56.0M | ||
| Q2 25 | $2.7M | $-49.3M | ||
| Q1 25 | $-1.0M | $33.6M | ||
| Q4 24 | $4.3M | $-31.6M | ||
| Q3 24 | $10.7M | $-40.5M | ||
| Q2 24 | $-1.6M | $-45.5M | ||
| Q1 24 | $-1.1M | $-55.5M |
自由现金流KLTRRGNX
| Q4 25 | $3.5M | $-52.8M | ||
| Q3 25 | $9.2M | $-56.5M | ||
| Q2 25 | $2.5M | $-49.7M | ||
| Q1 25 | $-1.3M | $32.6M | ||
| Q4 24 | $4.2M | $-32.7M | ||
| Q3 24 | $10.6M | $-40.9M | ||
| Q2 24 | $-1.8M | $-46.0M | ||
| Q1 24 | $-1.2M | $-56.0M |
自由现金流率KLTRRGNX
| Q4 25 | 7.7% | -174.0% | ||
| Q3 25 | 20.9% | -189.9% | ||
| Q2 25 | 5.7% | -232.8% | ||
| Q1 25 | -2.9% | 36.6% | ||
| Q4 24 | 9.2% | -154.2% | ||
| Q3 24 | 23.9% | -168.9% | ||
| Q2 24 | -4.2% | -206.2% | ||
| Q1 24 | -2.8% | -358.5% |
资本支出强度KLTRRGNX
| Q4 25 | 0.3% | 1.7% | ||
| Q3 25 | 0.3% | 1.7% | ||
| Q2 25 | 0.3% | 1.8% | ||
| Q1 25 | 0.6% | 1.2% | ||
| Q4 24 | 0.2% | 5.1% | ||
| Q3 24 | 0.2% | 1.3% | ||
| Q2 24 | 0.5% | 2.1% | ||
| Q1 24 | 0.2% | 3.6% |
现金转化率KLTRRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KLTR
| Subscription | $42.7M | 94% |
| Professional Services | $2.9M | 6% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
